Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam

被引:15
|
作者
Kaljee, Linda M. [1 ]
Pham, Van
Son, Nguyen Dinh
Hoa, Nguyen Thai
Thiem, Vu Dinh
Canh, Do Gia
Kim Thoa, Le Thi
Ali, Mohammad
Ochiai, Rion Leon
Danovaro-Holliday, M. Carolina
Acosta, Camilo J.
Stanton, Bonita
Clemens, John
机构
[1] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA
[3] Prov Prevent Med Ctr, Hue City, Thua Thien, Vietnam
[4] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[5] Ha Noi Med Univ, Hanoi, Vietnam
[6] Int Vaccine Inst, Seoul, South Korea
[7] Wayne State Univ, Sch Med, Carman & Ann Adams Dept Pediat, Detroit, MI USA
关键词
children/adolescents; enteric disease; vaccination; typhoid fever; Viet Nam;
D O I
10.1111/j.1365-3156.2006.01751.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVES To identify demand for Vi typhoid fever vaccine for school-age children; obstacles and enabling factors for vaccine delivery; and socio-behavioural factors associated with trial participation and possible predictors of future vaccine acceptance, in Hue City, Viet Nam. METHODS Pre- and post-trial surveys of randomly selected households with children aged 6-17 years. Simple multinomial logistic analyses for ratios of relative risks (RRR) and significance on trial participation by demographics and variables related to typhoid fever, vaccination, and pre-trial experiences with information and consents. Multiple logistic regressions to assess differences in participation based on child's characteristics. RESULTS As many as 62.6% of households let all school age children participate, 10.2% let some participate, and 26.8% let none of their children participate in the trial. Factors associated with all children participating included past use of healthcare facilities (RRR, 0.45; 95% CI, 0.24-0.83), knowledge of vaccines (RRR, 0.17; 95% CI, 0.03-0.86), and perceived causes of typhoid fever (RRR, 0.90; 95% CI, 0.81-0.99). Factors associated with some children participating included utilization of healthcare facilities (RRR, 0.08; 95% CI, 0.01-0.66) and perceived severity of typhoid fever (RRR, 0.64; 95% CI 0.46-0.88). Participation was associated with satisfaction regarding pre-vaccination information and consent procedures. Children and adolescents were active decision-makers. Only 14 of 461 (2.2%) respondents would not use the Vi vaccine in the future for their child(ren). CONCLUSIONS Inter-related factors contribute to participation in a clinical vaccine trial, which may differ from desire to participate in a public health campaign. Educational campaigns need to be targeted to children and adolescents, and consideration for assent procedures for minors. Obtaining informed consent may affect trial participation within a social and political system unaccustomed to these procedures.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 50 条
  • [31] PERSISTENCE OF ANTIBODY-TITERS 3 YEARS AFTER VACCINATION WITH VI POLYSACCHARIDE VACCINE AGAINST TYPHOID-FEVER
    TACKET, CO
    LEVINE, MM
    ROBBINS, JB
    VACCINE, 1988, 6 (04) : 307 - 308
  • [32] The treatment of typhoid fever by intravenous injections of polyvalent sensitized typhoid vaccine sediment - Studies in typhoid immunization VI
    Gay, FP
    Chickering, HT
    ARCHIVES OF INTERNAL MEDICINE, 1916, 17 (02) : 303 - 328
  • [33] Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children
    Lanh, MN
    Bay, PV
    Ho, VA
    Thanh, TC
    Lin, FYC
    Bryla, DA
    Chu, CY
    Schiloach, J
    Robbins, JB
    Schneerson, R
    Szu, SC
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14): : 1390 - 1391
  • [34] A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
    Schwartz, Eli
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (22): : 2191 - 2192
  • [35] Prevention of Typhoid Fever by Existing Improvements in Household Water, Sanitation, and Hygiene, and the Use of the Vi Polysaccharide Typhoid Vaccine in Poor Urban Slums: Results from a Cluster-Randomized Trial
    Im, Justin
    Khanam, Farhana
    Ahmmed, Faisal
    Kim, Deok Ryun
    Kang, Sophie
    Tadesse, Birkneh Tilahun
    Chowdhury, Fahima
    Ahmed, Tasnuva
    Aziz, Asma Binte
    Hoque, Masuma
    Islam, Md Taufiqul
    Park, Juyeon
    Liu, Xinxue
    Sur, Dipika
    Pak, Gideok
    Jeon, Hyon Jin
    Zaman, Khalequ
    Khan, Ashraful Islam
    Qadri, Firdausi
    Marks, Florian
    Kim, Jerome H.
    Clemens, John D.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2022, 106 (04): : 1149 - 1155
  • [36] A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
    Sur, Dipika
    Ochiai, R. Leon
    Bhattacharya, Sujit K.
    Ganguly, Nirmal K.
    Ali, Mohammad
    Manna, Byomkesh
    Dutta, Shanta
    Donner, Allan
    Kanungo, Suman
    Park, Jin Kyung
    Puri, Mahesh K.
    Kim, Deok Ryun
    Dutta, Dharitri
    Bhaduri, Barnali
    Acosta, Camilo J.
    Clemens, John D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (04): : 335 - 344
  • [37] Design of T cell epitope rich OmpC peptide and its conjugation with Vi-polysaccharide: a candidate vaccine for typhoid fever
    Haque, Shabirul
    Jailkhani, Bansilal
    Sengupta, Sanjukta
    Mukhopadhyay, Asok
    Bhan, Maharaj Kishan
    Kumar, Ramesh
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [38] Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV)
    Voysey, Merryn
    Pollard, Andrew J.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (01) : 18 - 24
  • [39] Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits
    Panchanathan, V
    Kumar, S
    Yeap, W
    Devi, S
    Ismail, R
    Sarijan, S
    Sam, SM
    Jusoh, Z
    Nordin, S
    Leboulleux, D
    Pang, T
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2001, 79 (09) : 811 - 817
  • [40] A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; Expanding the use of Vi polysaccharide vaccine in Southeast China: A cluster-randomized trial
    Jin Yang
    Camilo J Acosta
    Guo-ai Si
    Jun Zeng
    Cui-yun Li
    Da-bin Liang
    R Leon Ochiai
    Anne-Laure Page
    M Carolina Danovaro-Holliday
    Jie Zhang
    Bao-de Zhou
    He-zhuang Liao
    Ming-liu Wang
    Dong-mei Tan
    Zhen-zhu Tang
    Jian Gong
    Jin-Kyung Park
    Mohammad Ali
    Bernard Ivanoff
    Gui-chen Liang
    Hong-hui Yang
    Tikki Pang
    Zhi-yi Xu
    Allan Donner
    Claudia M Galindo
    Bai-qing Dong
    John D Clemens
    BMC Public Health, 5